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Abstract
Achieving adequate glucose control in critically ill patients is a complex but important part of optimal patient
management. Until relatively recently, intermittent measurements of blood glucose have been the only means of
monitoring blood glucose levels. With growing interest in the possible beneficial effects of continuous over
intermittent monitoring and the development of several continuous glucose monitoring (CGM) systems, a round
table conference was convened to discuss and, where possible, reach consensus on the various aspects related to
glucose monitoring and management using these systems. In this report, we discuss the advantages and limitations
of the different types of devices available, the potential advantages of continuous over intermittent testing, the
relative importance of trend and point accuracy, the standards necessary for reporting results in clinical trials and for
recognition by official bodies, and the changes that may be needed in current glucose management protocols as a
result of a move towards increased use of CGM. We close with a list of the research priorities in this field, which will
be necessary if CGM is to become a routine part of daily practice in the management of critically ill patients.
Review
Introduction
Achieving adequate glucose control in ICU patients is
complex and difficult to perform optimally. Until relatively
recently, intermittent blood-gas analyzer and central
laboratory measurements of blood glucose from arterial
blood samples have been the only means of monitoring
blood glucose levels [1]. However, intermittent measure-
ments are limited by the workload associated with the sam-
pling process and the potential that between-measurement
events may be missed. With growing interest in the possible
beneficial effects of continuous over intermittent monitor-
ing and the development of several continuous glucose
monitoring (CGM) systems, a round table conference was
convened in March 2013 to discuss and, where possible,
reach consensus on various aspects related to glucose
monitoring and management. Leading experts in the field
of glucose control in ICU patients and invited members of
interested industry companies joined for presentation and
discussion. After the meeting, a draft report was circulated
to all participants by email for critical review. Representa-
tives of the invited industry companies were asked to
include a brief summary of their devices in the additional
file of this report (Additional file 1), but, other than
participation in the open discussion periods of the meeting,
had no influence on content.
Continuous glucose monitoring
Definitions
CGM has been proposed as a means to improve manage-
ment of dysglycemia. Although termed ‘continuous’, current
systems still sample intermittently, with a measurement
interval of a few milliseconds up to 15 minutes. Some
systems average the frequent intermittent measurements
and display them as a single reading or moving average,
updated regularly. Nevertheless, such measurements can be
considered as having ‘real-time’ value especially when
compared to their intermittent counterparts, although
physiological or data processing lag time may be present
depending on the sampled body fluid. Two factors can be
considered when defining ‘continuous’: the frequency of
actual glucose measurements and the immediacy of the
data display. Clearly, measurements need to be frequent
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enough to capture all glucose dynamics. Based on current
knowledge of the physiology of glucose and insulin metab-
olism in non-critically ill patients [2], an interval of 10 to
15 minutes between measurements is the likely maximum
interval that would detect most glycemic dynamics,
although faster dynamics may be observed when parenteral
nutrition is modified and particularly when an intravenous
glucose bolus is administered. The Clinical and Laboratory
Standards Institute (CLSI) guidelines use 15 minutes as the
cutoff for their definition of continuous monitoring [3], but
which cutoff should be used to separate ‘continuous’ from
‘frequent intermittent’ sampling is debatable. More data on
glucose trends in the critically ill are needed before clinic-
ally relevant sampling frequencies can be defined. The real-
time output of CGM devices should be as instantaneous as
possible, although there will generally be a lag period, the
duration of which will depend on the site and frequency of
sampling and data processing. The continuous display
enables trends to be identified and visualized.
Importantly, the purposes of any such device are to
improve clinically relevant outcomes and to reduce associ-
ated nursing workload and ideally costs. Although the
overall accuracy of many CGM systems is less than that of
intermittent systems using central laboratory testing [4],
this limitation is to some degree mitigated by the ability to
follow the direction of change in glucose levels, theoretic-
ally allowing earlier intervention to maintain blood glu-
cose concentrations within acceptable ranges. A less-often
cited advantage is the decreased need for multiple finger-
pricks or blood pulls with a continuous system, which
may reduce patient discomfort and nurse workload [5,6].
Several CGM systems are now available for clinical use
and early results from clinical trials in critically ill adults
[7-14] and children [15,16] have been published. However,
no studies have assessed clinical outcomes using the
continuous approach compared to an intermittent system;
furthermore, the different sensors used, the different com-
parators, and the lack of standardized performance metrics
make it difficult to compare results.
Overview of techniques for glucose measurement
The three predominant techniques currently used for
continuously measuring glucose levels in the ICU involve
glucose oxidase, mid-infrared spectroscopy and fluorescence.
The glucose oxidase technique is based on the sensing
of hydrogen peroxide (H2O2) released when glucose is
converted to glucolactone: the greater the concentration
of glucose, the more H2O2 will be released and the
stronger the signal. Results can be influenced by interfer-
ence from molecules other than glucose (for example, uric
acid, acetaminophen and salicylic acid) which oxidize the
H2O2.
Mid-infrared spectroscopy detects an absorption spectrum
for glucose in plasma using different wavelength filters.
Fluorescence techniques rely on quenched chemical
fluorescence to measure glucose concentration [17]. Fluor-
escence glucose sensors are associated with a foreign body
response, are sensitive to local pH and/or oxygen, and
require a light source.
Monitoring sites: clinical experience
Glucose can be measured in whole blood, plasma, intersti-
tial fluid, and microdialysis fluid and values will vary
according to which fluid is used [18]. Generally, plasma glu-
cose is considered the ‘gold standard’. Glucose dissolves in
water and because plasma has a higher water concentration
(approximately 93%) than do red blood cells (approximately
71%), plasma will have a higher glucose concentration than
will whole blood. The difference in laboratory-measured
glucose concentration between whole blood and plasma
will also vary with the hematocrit. Because some glucose
diffuses from the plasma to interstitial fluid and tissues as
blood circulates through the capillary system, arterial blood
glucose is usually higher than venous glucose. Arterial
blood glucose and capillary blood glucose are generally
similar, although when blood glucose levels change rapidly,
there may be a delay before similar changes are seen in
capillary blood. Microdialysis concentrations tend to be
slightly lower than those present in the surrounding tissue
or blood.
The degree of invasiveness of a CGM technique varies
from highly invasive (for example, intravascular devices)
through the minimally invasive subcutaneous techniques,
to non-invasive transdermal devices. Although studies com-
paring the accuracy and performance of more versus less
invasive CGM systems have not yet been performed, pre-
liminary data suggest that, moving through the spectrum
from invasive to non-invasive, accuracy generally decreases
as does the risk of complications, including infections. The
type of monitor selected should be adjusted to patient char-
acteristics, including the severity of illness of the patient
and the type of access available. For example, a severely ill,
unstable ICU patient will likely already have arterial and/or
central venous lines in situ allowing invasive intravascular
monitoring, whereas a stable patient ready for ward transfer
can be monitored using a less- or non-invasive device.
Moreover, severely ill patients are more likely to be receiv-
ing mechanical ventilation and/or sedative agents, making
clinical symptoms of hypoglycemia more difficult to detect
and perhaps arguing in favor of the more accurate invasive
devices. When comparing devices it is essential to state
which reference measurement technique is used so that
results can be easily compared. Whenever possible, arterial
glucose measurements with a blood gas analyzer or by a
central laboratory should be used as the comparator as
these are the most accurate and reproducible [1]; when this
is not possible, or when the device under study uses venous
sampling, venous blood glucose should be used as the
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comparator. When venous sampling is used, the specific
vessel should be defined.
Intravascular CGM devices can be divided into three
groups: (1) those that have an intravascular sensor inserted
into the lumen of an artery or peripheral/central vein and
directly measure the blood glucose concentration without
consuming blood in the process; (2) those in which a small
blood sample is taken from the intravascular catheter and
passed over an external sensor; and (3) those in which a
blood sample is re-circulated after passing through an
external sensor without blood loss. The accuracy of intra-
vascular microdialysis probes will vary according to their
position - for example, if integrated into the central venous
catheter, a much larger membrane will be possible than if
positioned in a smaller peripheral vein catheter, allowing a
greater area for equilibration and a more rapid and reliable
result [19]. Recent studies using a central venous catheter
with a microdialysis membrane have demonstrated good
agreement between microdialysis glucose measurements
and reference venous and arterial blood gas values in
patients undergoing major abdominal surgery or cardiac
surgery [20,21].
Interstitial fluid glucose is generally measured with
subcutaneous probes, often inserted on the abdominal
wall or upper arm. Interstitial fluid glucose levels depend
on the rate of glucose diffusion from plasma to the inter-
stitial fluid and the rate of uptake by subcutaneous tissue
cells; hence, they are influenced by blood flow, the meta-
bolic rate of adjacent cells, capillary permeability, degree
of hydration or edema, and so on, all of which may be
altered in critically ill patients [18]. Several subcutaneous
devices have been tested in critically ill patients and have
been shown to have good agreement with reference arter-
ial and venous samples [12,22-24]. Moreover, similar ac-
curacy has been reported in critically ill patients with and
without shock requiring norepinephrine therapy [22], and
in cardiac surgery versus non-critically ill patients [25,26].
Nevertheless, the accuracy of interstitial fluid monitoring
needs to be further investigated, in particular in unstable
patients. One concern with subcutaneous interstitial fluid
probes is the tissue trauma created during insertion, such
that measurements may be less accurate for several hours
after insertion. There is a time lag between change in
blood glucose and that measured in the interstitial fluid,
which is, however, unlikely to result in ineffective treat-
ment in case of an emerging hypo- or hyperglycemic event
[27-30]. The clinical relevance of this time-lag needs to be
contrasted against current practice with a typical delay of
5 to 10 minutes to take the sample and to measure glu-
cose on an analyzer.
Transcutaneous devices are also being developed. One
such device uses a biosensor that can measure transdermal
glucose flux, which is proportional to the blood glucose
concentration. The skin is prepared by microabrasion to
remove the dead surface cells and the biosensor then ap-
plied, using the glucose oxidase reaction to create a mea-
sureable signal for interstitial glucose. In pilot studies of
cardiac surgery patients, good agreement with peripheral
blood was demonstrated [31,32].
All techniques have limitations related in part to the
sampling site used (venous, arterial or capillary blood,
plasma, and interstitial fluid) [18], but also to the need for
anticoagulation with some intravascular devices, problems
of local inflammation, and need for recalibration. Rice and
Coursin [33] recently proposed a list of attributes for the
‘ideal’ CGM system (Box 1). For all CGM systems, specific
performance characteristics related to the clinical utility of
the system need to be clearly defined (Box 2).
Trend accuracy versus point accuracy
One of the key advantages of CGM systems is their ability
to identify and display trends in blood glucose measure-
ment. Hence, when considering the performance of these
devices, additional metrics may need to be developed to
complement current assessment of accuracy. Point accuracy
is defined as the difference between the current displayed
blood glucose value and the current true blood glucose
value. Trend accuracy is defined as the degree to which an
estimate of the rate of change in blood glucose concentra-
tion over a given time interval approximates the true rate
of change. Further research is required to establish the
duration over which trend accuracy should be calculated
and the relative importance of point accuracy versus trend
accuracy in terms of clinical outcomes.
In theory, the use of trending could have several potential
advantages over individual values (Figure 1), including: that
it is less sensitive to random noise, because, if present, noise
will be filtered out by the trend line, at least when the
period used to calculate the trend is long enough; there is
little effect of bias - the presence of a constant over- or
under-shoot of the value will not affect the trend. However,
Box 1. Suggested criteria for the ideal continuous
glucose monitoring system [33]
Rapid: very little lag between blood glucose and the measured value.
Accurate: each measurement should be within accuracy guidelines
suggested recently [1].
Free of interference: minimal, if any, important interference, such
as drugs or physiologic perturbations.
Inert: the sensor should not react with the tissue or form a coating
rendering the device inaccurate over time.
Robust: the system must be able to perform within the dynamic
and busy ICU and operative setting.
Minimally invasive
Cost-effective
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there are also several disadvantages. First, there is a lag time
when calculating the trend that will depend on the
frequency of sampling and the number of measurements
and time-lapse over which those measures are used. With
longer time intervals between measurements, trending will
reflect real changes less accurately, certainly when changes
are rapid and intervals are long. Second, if there is a lag
time or a bias, extrapolation of the trend line can amplify
the error. Third, most current glycemic control protocols
rely on PID (proportional, integral, derivative) control with
insulin rates determined as a function of the current blood
glucose (P), accumulation of historical blood glucose values
(I), and the trend (rate of change) in blood glucose (D).
Hence, for current protocols, all three aspects need to be
accurate; it is not sufficient just to have accurate trend
accuracy - point accuracy also needs to be good.
Thus, at the present time, both good point accuracy
and good trend accuracy are required to achieve optimal
glycemic control. However, the more continuous the
measurement, the clearer and more reliable the trend
will become. In the future, use of algorithms designed
specifically for CGM may also reduce the need for highly
accurate point measurements. The period of time over
which trend should be assessed will depend on lag time
and may also depend on the type of patient.
Standards for reporting performance
Standards for reporting of clinical trials of CGM systems
need to be developed so that results can be easily compared.
In this context, we can consider factors related to the
patients and the device and those related to the impact of
the device on clinical outcomes. In terms of the device and
patient, several aspects need to be reported regarding demo-
graphics (age, gender, comorbidities, including diabetes,
disease severity), use of vasoactive drugs, design (single-
center versus multicenter, type of center, number of samples,
comparator), glucose targets (target range), definition of
hypoglycemia and hyperglycemia, time in range, analytical
and clinical accuracy, number of patients unable to monitor
and reasons, down-time (time needed for calibration when
no signal/reading available) and time to display, and safety
(bleeding events, infections, outliers, alarm performance).
In terms of characterization of accuracy of the system
being tested versus the comparator, the Bland-Altman plot
remains indispensable, showing the difference between the
two measurements either as a function of the average of
the two measurements or, when there is a ‘gold standard’, as
a function of the comparator [34]. The 95% confidence
interval (1.96 × standard deviation) of a tested blood glu-
cose meter against a gold standard can be deduced from
these plots. Various grid systems have also been proposed,
of which the Clarke error grid [35] is currently the most
widely used. However, this grid was not designed for CGM
systems and does not reflect rapid changes in the blood
glucose level or account for potential errors in insulin
dosing. As such, the so-called continuous glucose error grid
analysis (cEGA) has been proposed, which is designed to
capture errors in the rate and direction of change in glucose
between measurement methods [36]. This technique,
initially developed for outpatient care, is an interesting
approach but relatively complex, requiring specific software
and frequent sampling [37]. The R-deviation is another
potential metric to assess the accuracy of CGM systems
[38]. This value is a numerical metric of rate of change
accuracy, based on the deviation between the rates of
change in reference and test sensor glucose fluctuations.
How to report on the impact of a device when used with
a treatment protocol is perhaps less clear. For this purpose,
three domains of glycemic control can be considered:
hyperglycemia, hypoglycemia, and glycemic variability [39];
glucose complexity has been suggested as a possible fourth
domain [40]. The three domains are all associated with
increased mortality in critically ill patients [39] and, as such,
the number and duration of hypo- and hyperglycemic epi-
sodes (using pre-specified parameters), the time in target,
the degree of glucose variability (and possibly complexity)
should all be reported when assessing the clinical impact of
a new device, in addition to clinical outcomes, including
mortality and morbidity measures. Further study is needed
to determine how best to define trend and hypoglycemia
Box 2. Performance characteristics related to the clinical
utility of continuous glucose monitoring systems that
need to be clearly defined for each system
Frequency of sampling
Delay to display
Lag time
Biofilm development
Measurement accuracy
Reliability (time to sensor failure, frequency and duration of data
gaps)
Need for and frequency of calibration
Ability to recognize and correct for interference
Automation
Need for anti-coagulation
Safety
Site of access
Handling of outlier values
Alarms
Clinical effectiveness (that is, impact on glucose control and
prevention of hypoglycemia)
Cost-effectiveness
Possibility of combining glucose monitoring with other
measurements
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(including sensitivity and specificity) for regulatory approval
(see below).
Alarms, warning signals
Alarms on CGM systems generally concern the three
domains of glycemic control listed earlier. Determining at
which value alarms should be set for each domain remains
difficult. The clinical impact of hypo/hyperglycemia will
vary according to the degree and time away from normal
values (Figure 2), with considerable overlap among individ-
uals. Several studies have suggested that patients with acute
coronary syndromes and severe brain injury may be more
sensitive to low blood glucose levels [41,42], at least in the
absence of tight glucose control [43]. Therefore, in some
Figure 1 Schematic representation of the potential advantages of using trends. (A) If imprecision or noise is random or normally distributed,
the trend line will filter it out. (B) If the measurement system has a fixed bias, trend will not be affected but individual values could be. (C) When trying
to predict future events, trend may be clinically more important than the current absolute blood glucose value.
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groups of critically ill patients, target glucose ranges may
need to be set higher than in other groups. Generally, a
blood glucose ≤40 mg/dl is considered to represent severe
hypoglycemia [1,44] and a level of 41 to 70 mg/dl moderate
hypoglycemia [1], but studies have used different defini-
tions. Hyperglycemia is variably considered as values >140
or 180 mg/dl. Glycemic variability is even more difficult to
define; a relatively high value of the coefficient of variation
of >20% has been suggested to define high variability,
because it is associated with worse outcomes than values
<20%. Variability is also related to ongoing therapy.
Glycemic targets will also vary according to individual
patient characteristics, including age, comorbidities (notably
diabetes), type of patient (for example, surgical versus
medical), and so on. Alarm settings therefore need to be
adjustable for individual patients. Further study is needed
to define optimal target ranges for different groups of
patients and to clarify the impact of alarms on clinical prac-
tice and patient outcomes. With the development of better
validated CGM systems and better knowledge of glucose
trends in the critically ill, alarms for trend changes will be
developed and have the potential to prevent hyper- and
hypoglycemia. Predictive alerts are already in use on some
devices inserted subcutaneously.
Criteria for approval by the official bodies
In terms of safety and effectiveness, it is unclear which
metrics should be used to indicate sufficient accuracy and
reliability. The CLSI has produced new standards for
point-of-care testing [45]; however, these standards may
not be applicable to CGM systems. In our 2013 Consensus
document, we suggested that the minimum standard for
glucose meters to be used in critically ill patients should be
that 98% of readings should be within 12.5% of a reference
standard (or within ±10 mg/dl for readings <100 mg/dl);
the remaining 2% of readings should be within 20% of a ref-
erence standard [1]. The mean absolute relative difference
should be cited and values should be <14%; values >18%
are considered to represent poor accuracy. For trend accur-
acy there is not yet an accepted metric. The R-deviation
may be useful, but further study is needed [38]. Other
concerns that need to be addressed include signal stability,
drift, variability, and drop-out; potential interferences
(for example, acidosis, hematocrit, bilirubin, hemoglobin,
medications and intravenous fluids); edema and nutritional
status; and number and characterization of outliers. As yet,
there are no clearly defined metrics for reporting what is
sufficient in terms of accuracy and reliability.
Insulin algorithms
An algorithm can be defined as ’a formalized sequence of
instructions for solving a complex problem in finite pro-
cessing steps’ [46]. Algorithms in the field of tight glucose
control are used to standardize care, for quality assurance
and to avoid intuitive decision making. An optimal system
should be accurate, safe, efficacious, simple to use, reliable,
flexible for different patient populations, assessable in real-
time, fit into workflow, require a low number of glucose
Figure 2 The clinical impact of hypo/hyperglycemia varies according to the degree away from normal values.
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measurements (if not based on CGM), and take into
account inter- and intrapatient variability and carbohydrate
intake. Algorithms should incorporate dynamic scale proto-
cols, instead of static sliding-scale protocols [47]. Although
early algorithms were paper-based [48,49], increasingly, glu-
cose control algorithms are computer-based, enabling more
complex protocols to be developed. Several studies have
demonstrated improved glucose control with computer-
based compared to paper-based algorithms [50-52]. A
common type of algorithm is the PID algorithm in which
deviation of the blood glucose value from the target range
is corrected by adjusting the dose of insulin using a linear
combination of absolute deviation, trend, and the sum
of past deviations [53]. Another main type of glucose
algorithm used in critical care is the model-based or
model-predictive control algorithm, which adjusts insulin
dose according to a mathematical model of the relationship
between blood glucose and insulin [54,55]. Better stan-
dardization of algorithm development is needed [56].
Many algorithms for glucose control have been developed.
Wilson and colleagues [57] identified 12 different algorithms
and, using blood glucose records from an actual hyper-
glycemic patient, calculated the insulin doses that would
have been recommended by each protocol. There was con-
siderable variability among protocols in patterns and ranges
of recommended insulin dose (range 27 to 115 units), and
adjustments to dose when nearing target glucose. Protocols
therefore behave differently and may have greater influence
on outcomes than the glucose measurement error. Different
algorithms may be better suited to various patient popula-
tions or clinical settings.
Clinical testing and comparison of algorithms is resource
intensive in terms of patients, staff, time, and costs. More-
over, the majority of algorithms for glycemic control in the
ICU are based on intermittent glucose measurements and
new algorithms will need to be designed if CGM systems
become more widely used. When comparing algorithms,
standard glucose-centric outcomes need to be reported,
including numbers of hypo- and hyperglycemic episodes.
One useful parameter that has been suggested is the cumu-
lative time-in-band, which calculates the percentage of
blood glucose values that fall within a specified range. This
measure is independent of sampling frequency, can be
applied to all algorithms and is simple to calculate; however,
it is only useful when comparing algorithms that target the
same blood glucose band.
In silico simulation models using ‘virtual’ ICU patients
have been suggested to reduce some of the burden of
clinical algorithm comparisons and to accelerate the assess-
ment process. These systems can be used to optimize
design parameters and safety features, test effects of
changes in nutrition or other medications and interven-
tions, and assess effects of measurement errors or delays.
At least four currently available ICU simulators are known:
the Cambridge [58], Virginia [59], Leuven [60], and Christ-
church [61] models and simulation models are beginning
to be used in the critical care setting of glycemic control.
Wilinska and colleagues used simulation to compare the
effects of different algorithms [62] and the performance of
a newly proposed algorithm [63]; the study results were
reproduced in the simulated populations. Although these
systems need further study, it seems likely that the virtual
patient will play an increasingly large role in the ongoing
development of CGM systems and glycemic control proto-
cols in the ICU setting.
The development of closed loop systems, which deliver
insulin in a glucose responsive fashion every 1 to 15 minutes
based on CGM measurements, is the most promising
approach to improve glucose control once CGM becomes
routinely available. Closed loop systems are being aggres-
sively pursued and may help modulate glucose delivery to
further reduce the risk of hypoglycemia. Automated
closed-loop glucose control based on continuous sub-
cutaneous glucose measurements and model predictive
control in critically ill adults was associated with better
glycemic control compared to a local sliding scale protocol
[64].
Priorities for research
The expert group defined eight areas where research should
help to advance glucose monitoring in the near future to
the likely benefit of critically ill patients. First, the different
devices for CGM need to be better validated in terms of
accuracy and reliability. Head-to-head comparisons are
needed, particularly for devices sampling different compart-
ments. Second, the clinical relevance of inaccuracies in
glucose measurements should be shown in error grids
adapted to current therapeutic algorithms. Third, glucose
trends in critically ill patients and subgroups need to be
more clearly characterized, so that better definitions of the
rate of change can be developed and, thereby, the frequency
of sampling needed to describe clinically relevant trends.
Fourth, the effect of different insulin treatment algorithms
on glucose variability should be studied with development
of new and enhancement of existing glucose control proto-
cols based on CGM. Fifth, development and validation of
metrics for trend accuracy are required. Sixth, universal
metrics to assess glycemic control and blood glucose
variability that could be used with continuous as well as
intermittent data should be defined and agreed upon.
Seventh, at a later time-point, randomized controlled trials
need to be conducted assessing the effects of CGM versus
intermittent systems on outcome in critically ill patients, in-
cluding assessment of patient-centered outcome measures
(glycemic control and morbidity incidence). Eighth, closed
loop systems for glucose control in critically ill patients
should be developed and eventually validated and assessed
in randomized controlled trials as above.
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Conclusion
CGM mandates the development of new approaches to the
analysis of parameters of glucose regulation, such as glucose
variability and glucose complexity, and also provides a tool
to help effect these analyses. While CGM systems clearly
have the potential to improve blood glucose control and
patient outcomes, this remains a potential that has not yet
been demonstrated in clinical practice. Future studies may
be able to demonstrate real clinical benefits and reveal the
optimal use of the different CGM systems (which system for
which patient). When discussing how best to assess CGM,
different goals can be considered, including maintenance of
specified target levels, which may vary in different patient
populations; avoidance of hypoglycemic events; assessment
of glucose variability; and degree of glucose complexity.
Most important, however, will be the impact of each device
on clinical outcomes, including better glucose control and
fewer hypoglycemic episodes; this is of far more relevance to
clinicians and patients than small differences in accuracy.
Additional file
: Summary of the current continuous glucose
monitoring devices (provided by the industrial sponsors of the
meeting, listed in alphabetical order).
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